SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced ...
2025--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the ...
About Autobahn Therapeutics Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting ...
Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., Bristol-Myers Squibb, TG Therapeutics, Inc ...
Hosted on MSN24d
Should You Retain Charles River Stock in Your Portfolio Now?Charles River has become the preferred research partner for Autobahn Labs ... the translation of academic discoveries into novel therapeutics. Under a contract development and manufacturing ...
The leading site for news and procurement in the pharmaceutical industry ...
He has the right to directly dispose of 50.0000001% of JSC ISC Autobahn. The LAWSUIT "Autobahn" has the right to dispose of 99.932% of JSC "DSK "Autobahn". "DSK Avtoban has the right to dispose of 95% ...
Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of $110.00. Roger Song has given his Buy rating due to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback